Enveda

Our Head of Capital Formation, Bigyan R. Bista, PhD, is in Geneva for the World Economic Forum 𝗔𝗻𝗻𝘂𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵 𝗥𝗼𝘂𝗻𝗱𝘁𝗮𝗯𝗹𝗲, 𝗠𝗮𝘆 𝟭𝟵–𝟮𝟬. Here's why he is there: The #pharma industry quietly walked away from #nature about thirty years ago. Synthetic compound libraries were easier to patent, scale, and mostly easier to pitch to a board. The dogma settled in. Most modern drug discovery still operates inside it. That was one of the more expensive mistakes the industry has made. Roughly half of FDA-approved small molecules trace back to a natural origin. More than 70% of our antimicrobials do. Aspirin, metformin, taxol, artemisinin, statins, and even GLP-1’s - each one came out of nature, not a synthetic library. Meanwhile, clinical trial failure rates have barely moved off 90%. Nature has been running the longest R&D program in history, and the field stopped reading the results. The next chapter of #AI in drug discovery has to be a different bet than the one most of the field is currently making. Most of the current excitement is about screening synthetic libraries faster. The harder, more useful work is reading, understanding, and designing from the chemistry evolution has been selecting for over four billion years. That's what Enveda has been building, but we are very much the minority. He'll also be bringing these important points to the table: • 𝗪𝗵𝘆 𝗔𝗜 𝗺𝘂𝘀𝘁 𝘀𝗼𝗹𝘃𝗲 𝘁𝗵𝗲 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗽𝗿𝗼𝗯𝗹𝗲𝗺 𝗶𝗻 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 – right chemistry + right biology from day one – not just the speed problem.    • 𝗛𝗼𝘄 𝗻𝗲𝘅𝘁-𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 that overcome liabilities of GLP-1 agonists are necessary to achieve durable, long-term metabolic health and healthy longevity.    • 𝗪𝗵𝘆 𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗮𝗿𝗶𝗹𝘆-𝘀𝗲𝗹𝗲𝗰𝘁𝗲𝗱 𝗰𝗵𝗲𝗺𝗶𝘀𝘁𝗿𝘆 𝗺𝗮𝘁𝘁𝗲𝗿𝘀 𝗳𝗼𝗿 𝗽𝗮𝗻𝗱𝗲𝗺𝗶𝗰 𝗰𝗼𝘂𝗻𝘁𝗲𝗿𝗺𝗲𝗮𝘀𝘂𝗿𝗲𝘀: 70%+ of antimicrobials originate from nature's library for a reason.    • 𝗪𝗵𝗮𝘁 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗮𝗻𝗱 𝗰𝗮𝗽𝗶𝘁𝗮𝗹 𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗳𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸𝘀 can enable AI-driven platforms to reach patients at scale? If you're there and you disagree, even better. Find him.

We're #hiring a new Accounts Payable Associate in Boulder, Colorado. Apply today or share this post with your network.

Which AI Biotech has a positive clinical readout, multiple mega-blockbuster clinical pipeline, and is expanding our knowledge of biology through chemistry? Enveda’s Founder & CEO, Viswa Colluru, PhD , will be presenting at UBS 𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗦𝘂𝗺𝗺𝗶𝘁 on 𝗠𝗮𝘆 𝟭𝟴, one of the industry's most selective forums bringing together institutional investors and the most innovative private companies shaping the future of biopharma. This marks the inaugural Private Biotech Innovation Summit under top-ranked analyst Mike Yee, bringing expanded depth, expertise, and insights to UBS's global research platform. Enveda is not just changing where and how we discover medicines, but our understanding of how life works. Join Viswa as he walks through the company's long-term vision and presents the unprecedented progress we've made, including ENV-294's Phase 1b data in atopic dermatitis and our growing clinical pipeline. He'll also join a panel moderated by Samantha Meadows-Ortiz, PhD on what actually differentiates AI platforms, where clinical proof points separate real signal from noise, and how platforms build lasting value beyond individual assets. Clinical validation is proving that our platform can consistently deliver differentiated medicines, and he’ll share what that means for the next generation of drug discovery. #biotech #drugdiscovery #AI #LearningFromLife

Did you know that a normal blood test only captures less than 0.1% of the chemistry in your blood? Imagine what the missing 99.9% could tell you. Enveda's mass spectrometry platform can identify hundreds of metabolites that standard blood panels never quantify or even name, many with important associations to health. Most people never get access to this kind of profiling. If you want to find out what is happening to your chemistry, we're running a metabolomics study at Edge City's Edge Esmeralda 2026 from June 1–8 in Healdsburg, CA. We're asking:   • How does your chemistry change over the course of a day?   • How do things like sauna and cold plunge shift it?   • How does it correlate with other digital biomarkers? Spots are limited. Find more info and sign-up at:  https://lnkd.in/gh7XT_E4 #𝗖𝗵𝗲𝗺𝗶𝘀𝘁𝗿𝘆 #𝗠𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰𝗛𝗲𝗮𝗹𝘁𝗵 #𝗠𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝘁𝗲𝘀

We're partnering with Enveda to run a metabolomics experiment during Edge Esmeralda 2026 🧬 For one week in June, 15 to 20 residents will receive free mass spec profiling of hundreds of circulating metabolites in their blood, drawn across multiple time points. Those who want to go deeper can also opt into paired pre- and post-exposure draws around cold plunge and sauna sessions, to see how their metabolism responds to acute thermal stress. Participants walk away with a personal metabolomic profile, interpretation of what those metabolites do, and a de-identified comparison to the rest of the cohort. This is the kind of deep phenotyping normally only available in research or clinical settings. The Enveda experiment sits inside Vital Futures, our anchor health track for Week 1, and stacks with Alethios studies, wearable data collection, and a dedicated Women's Health Summit running in parallel. Edge Esmeralda 2026 runs May 30 to June 27 in Healdsburg, California. The Enveda study runs June 1 to June 8. Open to confirmed EE26 ticket holders. If you don't have a ticket yet, apply to Edge Esmeralda 2026 at edgeesmeralda.com. Full write-up on our Substack ↓ https://bit.ly/4dk0ITB

We’ve built the world’s first Chemical Sequencer, but unlocking nature’s chemistry still requires more data and better ways to understand it. That’s why we’re deepening our collaboration with Tomáš Pluskal and his lab at IOCB Prague - Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, a global leader in natural product chemistry and plant metabolomics. We’re proud to support the PhD work of Filip Jozefov, whose research combines machine learning and mass spectrometry. Filip is developing new machine learning approaches using a rich dataset generated in the lab. These approaches improve the accuracy of molecular structure prediction, which is an essential step toward decoding nature’s chemistry at scale. Our ongoing collaboration supports our commitment towards advancing cutting-edge science, pushing the boundaries of what’s possible in structure prediction, and helping to shape the future direction of the field. #MachineLearning #MassSpectrometry #DrugDiscovery #Biotech

This Earth Day, we're reflecting on a simple but powerful idea: 𝗻𝗮𝘁𝘂𝗿𝗲 𝗵𝗮𝘀 𝗯𝗲𝗲𝗻 𝗿𝘂𝗻𝗻𝗶𝗻𝗴 𝘁𝗵𝗲 𝗹𝗼𝗻𝗴𝗲𝘀𝘁 𝗥&𝗗 𝗽𝗿𝗼𝗴𝗿𝗮𝗺 𝗶𝗻 𝗵𝗶𝘀𝘁𝗼𝗿𝘆. Life on Earth has built an extraordinary library of chemistry. Molecules shaped by survival, adaptation, and symbiosis. These compounds weren't designed in a lab. They were selected by nature to solve real biological challenges. At Enveda, we see this as an invitation.  🌿 𝗪𝗵𝗮𝘁 𝗶𝗳 𝘄𝗲 𝗰𝗼𝘂𝗹𝗱 𝗹𝗲𝗮𝗿𝗻 𝗳𝗿𝗼𝗺 𝘁𝗵𝗶𝘀 𝘃𝗮𝘀𝘁, 𝗹𝗮𝗿𝗴𝗲𝗹𝘆 𝘂𝗻𝗲𝘅𝗽𝗹𝗼𝗿𝗲𝗱 𝗰𝗵𝗲𝗺𝗶𝗰𝗮𝗹 𝘀𝗽𝗮𝗰𝗲? 🌿 𝗪𝗵𝗮𝘁 𝗶𝗳 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 𝗶𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗲𝗻𝗰𝗼𝗱𝗲𝗱 𝗶𝗻 𝘁𝗵𝗲 𝘄𝗼𝗿𝗹𝗱 𝗮𝗿𝗼𝘂𝗻𝗱 𝘂𝘀? Protecting biodiversity isn't just about preserving ecosystems. It's about safeguarding a living, evolving source of insight into human health. This Earth Day, we're reminded that the future of medicine may depend on how well we listen to nature. #EarthDay #Biodiversity #DrugDiscovery #NatureInspired

#Innovation doesn’t stop at the bench. Clinical trials are the bottleneck, but they don’t have to be. As we scale a pipeline across large, high-impact indications, execution needs to scale as well. That’s why we’re excited to welcome Chris Porter as SVP of Clinical Operations, bringing 25+ years of experience scaling global clinical programs and driving operational excellence.  The opportunity isn’t just to discover new molecules, it’s to deliver the next generation of medicines, 𝙛𝙖𝙨𝙩𝙚𝙧. Welcome, Chris! 🚀 Read more: https://lnkd.in/dBZ4PMZD